Medicines and older people: Polypharmacy, adherence and safety

Authors

  • Trisha Dunning

DOI:

https://doi.org/10.1080/20573316.2017.1352142

Keywords:

Diabetes, Older people, Medicines, Polypharmacy, Adherence/Compliance, Adverse events, Self-care

Abstract

Managing medicines is particularly complex for older people with diabetes as well as for family and health professional (HP) carers. Polypharmacy is common and often necessary because of pathophysiological changes associated with diabetes and older age. These changes affect prescribing decisions as well as methods used to administer medicines and to monitor medicine use. Beliefs and attitudes of people with diabetes and HPs about medicines influence their medicine preferences, behaviours and safety. Medicine errors and adverse events (AEs) are common reasons for admission to hospital and also occur in hospital. Insulin is the second most common medicine responsible for most errors and AEs after warfarin. Many older people with diabetes are on both these medicines. The purpose of this paper is to provide an overview of medicines error and AEs, discuss compliance/adherence and suggest some strategies to improve medicine safety in older people with diabetes.

Downloads

Download data is not yet available.

References

Sabate E., editor. Adherence to long term therapies: evidence for action. Geneva: World Health Organisation; 2003. p. 1–209.

Diabetes Australia (DA). A new language for diabetes: improving communication with and about people with diabetes. Canberra, DA: Diabetes Australia; 2011.

Diabetes Control and Complications Trial research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med. 1993;329:977–86. doi: 10.1056/NEJM199309303291401

United Kingdom Prospective Study (UKPDS 33, 34). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53, 854–65. doi: 10.1016/S0140-6736(98)07019-6

American Diabetes Association (ADA). 2016. Standards of medical care in Diabetes care.diabetesjournals.org/content/suppl/ … 1 … /2016-Standards-of-Care.pdf

Dunning T, Manias E. Medication knowledge and self-management by people with Type 2 diabetes. Aust J Adv Nurs. 2005;11:172–81.

Dunning T, Savage S, Duggan N, Martin P. The experiences and care preferences of people with diabetes at the end of life. J Hosp Palliat Nurs. 2012;14(4):293–302.

Mosby’s Medical Dictionary. 2009. 8th ed. Elservier.

Wise J. Polypharmacy: a necessary evil. Brit Med J. 2013. doi:10.1136/bmj.17033.

Byatt K. Polypharmacy: thoughtful or random? Brit Med J. 2014;348:g17. doi: 10.1136/bmj.g17

Austin R. Polypharmacy as a risk factor in the treatment of Type 2 diabetes. Diabetes Spectr. 2006;19(1):13–6. doi: 10.2337/diaspect.19.1.13

Green J, Hawley J, Rask K. Is the number of prescribing physicians an independent risk factor for adverse drug events in an elderly outpatient population? Am J Geriatr Pharmac. 2007;5(1):31–9. doi: 10.1016/j.amjopharm.2007.03.004

Jenkins R, Vaida A. Simple strategies to avoid medication errors. AAFP; 2007. http://www.aafp.org/fpm/2007/0200p41.html (accessed December 2009).

Gnjidic D, Hilmer S, Blyth F, Naganathan V, Waite L, Seibel MJ, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 2012;65:989–95. doi: 10.1016/j.jclinepi.2012.02.018

Berenznicki L, Peterson G. Adverse drug events and the role of pharmacy. Pharmacist. 2008;27(9):750–56.

Roughead E., Lexchin J. Adverse drug events: counting is not enough, action is needed. Med J Australia. 2006;184(7):315–6.

Von Laue N, Schwappach D, Koeck C. The epidemiology of preventable adverse drug events: a review of the literature. Wien Klin Wochenschr. 2003;115:407–15. doi: 10.1007/BF03040432

Gandhi T, Weingart S, Borus J, Seger AC, Peterson J, Burdick E, et al. Adverse drug events in ambulatory care. New Engl J Med. 2003;348:1556–64. doi: 10.1056/NEJMsa020703

Institute of Safe Medicine Practice (ISMP). 2008. www.ismp.org (accessed January 2011).

Newman B. Safety first. Nurs Rev. 2010, June:26.

Australian Institute of Health and Welfare (AIHW). Australian Hospital Statistics 2007–8. Canberra: AIHW; 2009.

Stowasser D, Allinson Y, O’Leary D. Understanding the medicine management pathway. J Pharm Pract Res. 2004;34:293–6. doi: 10.1002/jppr2004344293

Australian Commission on Quality and Safety in Health Care. 2010. http://www.health.gov.au/internet/safety/publishing.nsf/Content/NIMC_005_Medication-Safety-Alerts (accessed May 2010).

Rommers M, Teepe-Twiss I, Guchelaar H-J. Preventing adverse drug events in hospital practice: an overview. Pharmacoepidem Dr S. 2007;16:1129–35. doi: 10.1002/pds.1440

Dooley M, Wiseman M, McRae A, Murray D, Van De Vreede M, Topliss D, et al. Reducing potentially fatal errors associated with high doses of insulin: a successful multifaceted multidisciplinary prevention strategy. BMJ Qual Saf. 2011;20(7):637–44. (accessed December 2011). doi: 10.1136/bmjqs.2010.049668

Fowler D, Rayman G. Safe and effective use of insulin in hospitalised patients. London: National Health Service; 2010. http://www.diabetes.nhs.uk/document.php?o=1040 (accessed January 2011).

National prescribing service. NPS Medicinewise Older, wiser, safer. 2013. www.org.au/aolder -people

Bain S, Druyts E, Balijepalli C, Baxter C, Currie CJ, Das R, et al. Cardiovascular events and all-cause mortality associated with suplhonylureas compared to other antihyperglycaemic drugs: a Bayesian met-analysis of survival data. Diabetes Obes Metab. 2017;19(3):329–35. doi: 10.1111/dom.12821

Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of US concensus panel of experts. Arch Intern Med. 2003;163:2716–24. doi: 10.1001/archinte.163.22.2716

Budnitz D, Lovegrove M, Shehab N, Richards C. Emergency hospitalizations for adverse drug events in older Americans. New Engl J Med. 2011;365(21):2002–12. doi: 10.1056/NEJMsa1103053

Ernst E. Global prevalence of complementary medicines. World Health Organ Bull. 2000;78(2):252–57.

Egede LE, Ye X, Zheng D, Silverstein MD. The prevalence and pattern of complementary and alternative medicine use in individuals with diabetes. Diabetes Care. 2002;25:324–9. doi: 10.2337/diacare.25.2.324

Dunning T. Complementary therapies and diabetes. Complement Ther Nurs Midwifery. 2003;9:74–80. doi: 10.1016/S1353-6117(02)00143-9

Manya K, Champion B, Dunning T. The use of complementary and alternative medicine among people living with diabetes in Sydney. BMC Complem Altern M. 2012. doi:10.1166/1472-6882-12-2.

Bodenheimer T, Lorig K, Holman H, Grumbach K. Patient self-management of chronic disease in primary care. J Am Med Assoc. 2002;288(19):2469–75. doi: 10.1001/jama.288.19.2469

Haynes R, Yao X, Degani A, Kripalani S, Garg A, McDonald H. Interventions for enhancing medicine adherence. Cochrane Database Syst Rev Issue 4, ART No: CD000011. 2005. doi.10.1002/14651838.CD000011.pub2.

World health Organisation (WHO). Adherence to long-term therapies: evidence for action. Geneva: WHO; 2003.

Cramer J, Roy A, Burrell A, Fairchild C, Fuldeore M, Ollendorf D, et al. International Society for Pharmacoeconomics for Outcomes Research Working Group. Medication compliance and persistence: terminology and definitions. Value Health. 2007;11(1):4447.

Segal J. ‘Compliance’ to ‘Concordance’: a critical view. J Med Humanit. 2007;28:81–96. doi: 10.1007/s10912-007-9030-4

Bissonnette J. Adherence: a concept analysis. J Adv Nurs. 2008;63(6):634–43. doi: 10.1111/j.1365-2648.2008.04745.x

Pound P, Bitten N, Morgan M, Yardley L, Pope C, Daker-White G, et al. Resisting medicines: a synthesis of qualitative studies of medicine taking. Soc Sci Med. 2005;61:133–55. doi: 10.1016/j.socscimed.2004.11.063

Britten N. Commentary: does a prescribed treatment match a patient’s priorities? Brit Med J. 2003;327:840. doi: 10.1136/bmj.327.7419.840

Brian Haynes R, Ann McKibbon A, Kanani R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet. 1996;348:383–6. doi: 10.1016/S0140-6736(96)01073-2

Di Matteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care. 2002;40(9):794–11. doi: 10.1097/00005650-200209000-00009

Simpson S, Eurich D, Radjeedp S, Ross I, Varney J, Johnson J. A meta-analysis of the association between adherence to drug therapy and mortality. Brit Med J. 2006;333:15–8. doi: 10.1136/bmj.38875.675486.55

Bieszk N, Patel R, Heaberlin A. Detection of medication non-adherence through review of pharmacy claims data. Am J Health-Syst PH. 2003;15(60):360–6.

Kerse N, Buetow S, Mainous A, Young G, Coster G, Arroll B. Physician–patient relationship and medication compliance: a primary care investigation. Ann Fam Med. 2004;2(5):455–61. doi: 10.1370/afm.139

Yang Y, Dunning T, Rasmussen B. Chinese people’s experience of diabetes self-care in Australia. Diabetes Conquest. Summer: 2011:9–10.

Choudhry N, Fletcher R, Soumerai SB. Systematic review: the relationship between clinical experience and quality of health care. Ann Intern Med. 2005;142:260–73. doi: 10.7326/0003-4819-142-4-200502150-00008

The Pharmacy Guild of Australia. Medindex: a medicine compliance indicator. Canberra: The Pharmacy Guild of Australia; 2010. Http://www.medsindex.com.au (accessed November 2011).

Williams A, Manias E, Walker R. Interventions to improve medication adherence in people with multiple chronic conditions: a systematic review. J Adv Nurs. 2008;63(2):132–43. doi: 10.1111/j.1365-2648.2008.04656.x

Downloads

Published

2017-01-02

How to Cite

Dunning, T. (2017). Medicines and older people: Polypharmacy, adherence and safety. International Diabetes Nursing, 14(1), 10–15. https://doi.org/10.1080/20573316.2017.1352142

Issue

Section

Original Articles